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i).1. Introduction
Cardiovascular disease (CVD) is the leading cause of death world-
wide accounting for ~30% of all global deaths (Global status report on
non-communicable diseases 2010. Geneva, World Health Organization,
2011). The number of people who will die from CVD, mainly from
heart disease and stroke, are projected to increase and reach ~23.3 mil-
lion by 2030 (Mathers & Loncar, 2006). Despite major advances in the
treatment of patients with CVD, the morbidity and mortality associated
with CVD is high, and there remains signiﬁcant space for improvement
in new therapeutic interventions. Withmore potentially promising can-
didate therapeutics on the horizon, it is particularly important to test
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outcome for CVD patients through application of more effective
therapies.
The vascular endothelium is involved in many aspects of cardiovas-
cular health, including regulating vascular tone, hemostasis, thrombosis,
permeability and cell adhesion (Hirase & Node, 2012; Padilla et al.,
2014). The endothelium releases vasodilatory substances including
nitric oxide (NO), prostacyclin, C-type natriuretic peptide and
endothelium-derived hyperpolarizing factor, as well as vasoconstrictors
including endothelin-1, angiotensin II and thromboxane A2 (Needleman
et al., 1976; Moncada & Vane, 1981; Vanhoutte & Katusic, 1988;
Yanagisawa et al., 1988; Danser et al., 1994). In the healthy endothelium,
a balanced production of these factors plays an important preventative
role against vascular disease. However endothelial dysfunction disturbs
this balance and is associated with an increased risk of development of
CVD, such as atherogenesis, increased arterial stiffness (arteriosclerosis)
and associated hypertension.
2. Role of nitric oxide in vascular function
The discovery in the 1980s that NO could be produced endogenously
in the vasculature and exert vasodilatory effects led to a plethora of
studies which demonstrated its pleotropic effects including control of
blood pressure (BP) and vascular tone, neurotransmission and memory
formation, and host defencemechanisms. (Murad et al., 1978; Furchgott
& Zawadski, 1980; Ignarro et al., 1987; Moncada et al., 1988; Loscalzo &
Welch, 1995; Ignarro, 1999). NO is produced by a family of enzymes
known as NO synthases (NOS) (Michel & Feron, 1997) utilizing the sub-
strate L-arginine, molecular oxygen and nicotinamide adenine dinucle-
otide phosphate (Palmer et al., 1988). Three different isoforms of NOS
have been identiﬁed. Two of these are constitutively expressed in cells
and synthesise NO in response to increased intracellular calcium con-
centrations (Mayer et al., 1989; Mulsch et al., 1989; Moncada &
Palmer, 1990). The constitutive enzymes are known as neuronal NOS
(nNOS or NOS I) and endothelial NOS (eNOS or NOS III) (Michel &
Feron, 1997). The third isoform, termed inducible NOS (iNOS or NOS
II), is expressed in response to cytokines and other inﬂammatory factors
in a variety of cells including macrophages, neutrophils, cardiac
myocytes and endothelial cells (Szabo et al., 1994) and produces NO in-
dependent of changes in intracellular calcium concentration. More re-
cently it has become clear, however, that the production of either
constitutive NOS isoform can also be induced under certain conditions,
and that some tissues express low levels of iNOS already constitutively.
Under normal physiological conditions low levels of NO produced by
eNOS function as an important regulatorymessenger andmaintain ves-
sel tone (Amezcua et al., 1989; Loscalzo & Welch, 1995). NO-induced
vasodilatation is mediated by activation of soluble guanylate cyclase
(sGC), which converts guanosine triphosphate into cyclic guanosine
monophosphate (cGMP), and subsequently relaxes vascular smooth
muscle (Ignarro et al., 1981).
When NO is produced at elevated levels, such as from iNOS during
septic shock, NO can also have cytotoxic effects (Szabo et al., 1993).
While lower levels of constitutively produced NO are involved in the
regulation of mitochondrial activity by competing with oxygen at the
level of complex IV of the respiratory chain (Erusalimsky & Moncada,
2007), higher concentrations of NO have been shown to persistently in-
hibit mitochondrial function by nitrosylation of electron chain com-
plexes, in particular complex I (Clementi et al., 1998), and to cause
DNA damage (Delaney et al., 1993; deRojas-Walker et al., 1995). Endo-
thelial dysfunction is apparent in conditions such as hypertension, heart
failure, coronary artery disease, and atherosclerosis (Cai & Harrison,
2000; Vanhoutte, 2009; de Berrazueta et al., 2010). During these patho-
physiological conditions, eNOS-dependent conversion of L-arginine to
NO is impaired and thus NO bioavailability is reduced, concurrent
with decrease in NO-mediated vasorelaxation (Shimokawa et al.,
1991; Pou et al., 1992; Harrison, 1997; Wilcox et al., 1997). Enhanceddegradation of NO through scavenging by reactive oxygen species
(ROS), together with a reduction in production via eNOS, has also
been shown to be involved in reducing NO bioavailability (Harrison,
1997).
NO scavenging by ROS (in particular superoxide, O2−) is normally
controlled through a well-balanced production of NO and ROS (Cai &
Harrison, 2000). However during pathological conditionswhen the pro-
duction of NO decreases, the balance is perturbed (Griendling &
Fitzgerald, 2003). Superoxide reacts with NO to form peroxynitrite
(ONOO−) (Burney et al., 1999). Unlike NO, ONOO− is a potent pro-
oxidant which has been demonstrated to play a role in initiating lipid
peroxidation in both membranes and lipoproteins (Radi et al., 1991;
Rubbo et al., 1994; Thomas et al., 1998). Consequently, ONOO−-modi-
ﬁed low density lipoprotein has been shown to be involved in the accu-
mulation of cholesteryl esters in the fatty streaks characteristic of
atherosclerosis (Darley-Usmar et al., 1992; Guy et al., 2001).
Endothelial eNOS function may also become compromised as a re-
sult of increased oxidative stress. In atherosclerosis, for example, the
ﬂow of electrons from the reductase domain of eNOS to the oxidase do-
main (where L-arginine is oxidized) may become uncoupled from NO
production. Under these conditions, the enzyme produces O2− or
ONOO− in place of NO, a process referred to as “eNOS uncoupling”.
Uncoupling with a concomitant reduction in NO production occurs pri-
marily when eNOS becomesmonomeric (normally functional eNOS is a
dimer) (Zou et al., 2004; Forstermann &Munzel, 2006) and dissociation
and/or oxidation of the eNOS cofactor tetrahydrobiopterin has been
suggested to play a key role in uncoupling (Bendall et al., 2005).
Tetrahydrobiopterin availability is thought to be an important regulator
in activity and uncoupling of eNOS (Bendall et al., 2005). A recent study
in diabetes-induced mice suggests that tetrahydrobiopterin oxidation
leads to eNOS uncoupling and dysfunction, with exogenous administra-
tion of tetrahydrobiopterin promoting eNOS dimerization and normal-
isation of eNOS function (Abudukadier et al., 2013). Uncoupling of
eNOS has been demonstrated in human arteries and veins concomitant
with an increase in O2− production (Margaritis et al., 2013). Increases in
O2− production with consecutive endothelial dysfunction have been at-
tributed to eNOS uncoupling (Vasquez-Vivar et al., 1998), enhanced ac-
tivity of NADPH oxidase (an enzyme whose primary function is to
produce O2−) and xanthine oxidase (Jacobson et al., 2007).
Independent of oxidative stress and in addition to situations where
the availability of the NOS substrate L-arginine may be compromised,
a number of methylated arginine derivatives such as asymmetric
dimethylarginine act as endogenous inhibitors of NOS and thus of NO
generation (Böger, 2003). Asymmetric dimethylarginine concentrations
in plasma and tissues tend to increase in particular in patients with
heart and renal failure, contributing to risk of adverse outcomes in
such individuals (Visser et al., 2010).
Thus, endothelial dysfunction can be a result of several different
abnormalities affecting either production or availability of NO, and
under many pathophysiological conditions it is possibly a multi-
factorial process. Therefore, in most cases no causative treatment
option will be available. An attractive alternative to rescuing com-
promised endothelial function by correcting the true cause of the
malfunction is administration of an alternative source of NO. Current
treatment options for conditions such as angina, myocardial infarc-
tion, and heart failure include administration of organic nitrates,
for example glyceryl trinitrate (GTN) as a source of NO, causing cor-
onary vasodilatation (Marsh & Marsh, 2000). However, undesirable
side effects including a throbbing headache and orthostatic prob-
lems as well as tolerance development (limiting drug efﬁcacy
when administered for a prolonged period of time) have led to an in-
tense search for superior treatment options. As judged by the out-
come of several animal experimental studies, inorganic nitrite
(NO2−) administration may hold promise for the treatment of condi-
tions associated with endothelial dysfunction by improving vascular
function following biotransformation to NO; if found to be of value in
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native to organic nitrates in the future.
In this review, we discuss nitrite as a potential NO substitute, the
mechanisms involved in nitrate bioactivity and the role of nitrite in
cardiovascular health and function.
3. Nitrite as a potential nitric oxide substitute
The nitrate–nitrite–NOpathway has been proposed as an alternative
pathway for NO generation (Lundberg et al., 2008). NO produced
through this pathway has been proposed to represent a NOS-
independent alternative to the classical pathway in which NO is pro-
duced by oxidation of L-arginine in a reaction catalyzed by NOS
(Lundberg et al., 2008). Under normal physiological pH and oxygen ten-
sion, nitrite is an endogenous substance produced via the oxidation of
NO (in cells by cytochrome C oxidase (Torres et al., 2000), in blood prin-
cipally by ceruloplasmin; Shiva et al., 2006), and for many years nitrite
was simply considered a relatively inert metabolic end-product of NO.
However in the past decade, it has become apparent that under certain
conditions nitrite exerts potent biological effects, and several research
groups have identiﬁed that – particularly at low pH and oxygen tension
– nitrite is reduced by various nitrite reductases to NO (Cosby et al.,
2003; Webb et al., 2004; Rassaf et al., 2007; Shiva et al., 2007a;
Feelisch et al., 2008; Webb et al., 2008a; Aamand et al., 2009; Totzeck
et al., 2012a). Table 1 summarises various animal studies that have eval-
uated the efﬁcacy of nitrite as a vasodilator and/or BP lowering agent. In
vivo, nitrite is readily oxidized to nitrate (NO3−) by cellular and acellular
processes, and the latter can be reduced back to nitrite via mechanisms
involving the commensal bacterial ﬂora of the oral cavity and the gut as
well as reduction by xanthine oxidoreductase (XOR) in the host tissues
(Lundberg et al., 2009). This had led to the conceptualisation that a
‘nitrogen oxide cycle’ exists by which dietary sources of nitrite and ni-
tratemix inwith nitrite and nitrate produced by the oxidation of endog-
enous NO, suggesting a common circulating pool contributes to bodily
NO production.
An important physiological role for the nitrate–nitrite–NO pathway
is increasingly becoming apparent in the literature as its activity under
various conditions is being uncovered. It has been shown by a number
of research groups that nitrite-derived bioactivity is cardioprotective
by minimising cell death by apoptosis (Webb et al., 2004; Duranski
et al., 2005; Dezfulian et al., 2007; Shiva et al., 2007a, 2007b; Tripatara
et al., 2007), exerts anti-aggregatory effects (Srihirun et al., 2012; Corti
et al., 2013; Park et al., 2013; Velmurugan et al., 2013), inhibits hypoxic
and inﬂammatory pulmonary arterial hypertension (Baliga et al., 2012;
Sparacino-Watkins et al., 2012; Bueno et al., 2013), and that it increases
forearm blood ﬂow (FBF) and decreases BP by acting as a vasodilator
(Cosby et al., 2003; Dejam et al., 2007; Maher et al., 2008). In addition,
nitrate has been shown to improve exercise performance by reducing
the oxygen cost of exercise in skeletal muscle (Larsen et al., 2011).
Since this proﬁle of action resembles that of NO (and the latter can be
measured as a reaction product under speciﬁc reaction conditions) it
is widely believed that NO is the active principle that underpins most
if not all of the actions of nitrite (and nitrate). However, to the best of
our knowledge, this has not been unequivocally demonstrated. In this
review,we shall focus on the vasodilator effects of nitrite and dietary ni-
trate, together with the therapeutic potential of nitrite in acute heart
failure (AHF).
4. Dietary sources of nitrite and nitrate
4.1. Nitrate and conversion to nitrite
Nitrate (NO3−) is a ubiquitous constituent of our environment and
plays an essential role in the global nitrogen cycle. Symbiotic Rhizobia
bacteria located in the root nodules of leguminous plants can ﬁx atmo-
spheric nitrogen and hydrogen to produce ammonia which can betransported into the soil through plant roots, or by decomposition
(Gilchrist et al., 2010). The ammonia can be converted into nitrite by
denitrifying Nitrosomonas bacteria (and ammonia oxidizing Archaea)
in the soil and further to nitrate by Nitrobacter. Nitrate can be taken
up from the soil through transporter channels in plant root cells, provid-
ing a source of nitrogen for amino acids, proteins and nucleotides essen-
tial for growth and development (Wang et al., 2012). The genetic make-
up of the plant and thus the degree of nitrate inﬂux and efﬂux via
transporter channels can affect the nitrate content of the plant (Wang
et al., 2012). In addition, there are several environmental impacts affect-
ing thedegree of nitrogenﬁxation, including temperature, precipitation,
soil type and the extent of agricultural fertilizer use, and the intensity of
exposure to sunlight all of which can have an impact on the nitrate con-
tent of plants (Seljasen et al., 2012).
4.2. Dietary sources of nitrate
Green leafy vegetables are the major source of dietary nitrate. The
highest reported nitrate content is found in rocket (arugula; range
963–4305 mg nitrate/kg) (Santamaria et al., 1999), followed by radish
(range 1117–2993 mg nitrate/kg) (Santamaria et al., 1999), spinach
(range 961–2453 mg nitrate/kg) (Koh et al., 2012), beetroot (range
644–1800 mg nitrate/kg) (Tamme et al., 2006) and lettuce (range
428–1766 mg nitrate/kg depending on type) (Santamaria et al., 1999).
Cured meats are also a source of dietary nitrates and nitrites through
theuse of potassiumand sodiumnitrate andnitrite as curing/preserving
agents in these products (Binkerd & Kolari, 1975; Kim & Conca, 1990).
Drinking water is another source of nitrate (Knobeloch et al., 2013;
Nemčić-Jurec et al., 2013); the concentration of nitrate in drinking
water will vary according to geographical location, regional rules re-
garding safe levels of nitrate in tap water, or the consumption of bottled
water (Espejo-Herrera et al., 2013).
4.3. Route of dietary nitrate after consumption
Tracer studies with the stable nitrogen isotope 15N revealed that
about 60% of an oral 15N-nitrate dose ingested is excreted via the kid-
neys within the following 48 h; the fate of the remainder is unclear
and assumed to be subject to metabolic transformation to other
nitrogen-containing species (Wagner et al., 1984). About 25% of the cir-
culating pool of nitrate is actively taken up from blood via an anion ex-
change channel called sialin (Qin et al., 2012) and secreted by the
salivary glands into saliva (Lundberg et al., 2008). The salivary nitrate
is reduced to nitrite by commensal bacteria (Actinomyces and Veillonella
spp.) residing on the surface of the tongue (Tannenbaum et al., 1976;
Pannala et al., 2003; Doel et al., 2005). Nitrite is then swallowed into
the stomach; in this strongly acidic environment nitrite is protonated to
form nitrous acid (HNO2; pKa 3.15; the pKa is the pH at which 50% of
the acid is dissociated), and can spontaneously give rise to the generation
of NO through the following sequence of reactions: 2HNO2→ H2O +
N2O3 and N2O3↔ NO+ NO2 (Butler & Feelisch, 2008), or re-enters the
circulation as nitrite (Benjamin et al., 1994; Lundberg et al., 1994). This
cycle is known as the ‘enterosalivary recirculation pathway’ of nitrate.
Several studies have highlighted the importance of oral bacteriaﬂora
in the reduction of nitrate to nitrite. In earlier studies by Lundberg and
Govoni (2004), the authors showed that avoiding swallowing after ni-
trate ingestion can abrogate increases in plasma nitrite (Lundberg &
Govoni, 2004). In 2008 Govoni and colleagues expanded this work by
studying the effects of commercially available antibacterial mouthwash
on salivary and plasma levels of nitrate and nitrite following an oral in-
take of dietary nitrate (sodium nitrate) in healthy subjects. The authors
reported that rinsing the mouth with antibacterial mouthwash prior to
ingestion of nitrate reduces the conversion to nitrite in the saliva and at-
tenuates the rise in plasma nitrite (Govoni et al., 2008). To corroborate
these ﬁndings further, Petersson et al. (2009) explored the role of oral
commensal bacteria in bioactivation of dietary nitrate to nitrite and
Table 1
Experimental studies investigating the efﬁcacy of nitrite on vasorelaxation and blood pressure. A summary of in vitro and in vivo studies that have evaluated the efﬁcacy as a vasodilator.
Adenosine tri-phosphate (ATP), aldehyde dehydrogenase 2 (ALDH2), blood pressure (BP), cyclic guanosine monophosphate (cGMP), deoxyhemoglobin (deoxyHb), endothelial nitric
oxide synthase (eNOS), glyceryl trinitrate (GTN), hemoglobin (Hb), mean arterial pressure (MAP), myoglobin (Mb), nitric oxide (NO), oxyhemoglobin (oxyHb), red blood cells (RBC), sol-
uble guanylate cyclase (sGC), systemic arterial pressure (SAP), xanthine oxidase (XO), xanthine oxidoreductase (XOR).
Species Condition/model Nitrite reductase Dose/route/timing administration
of nitrite
Results Reference
Mouse Hypertension model. Wild type
compared to eNOS−/−mice
eNOS from RBC
(non-endothelial)
Endogenous systemic nitrite levels eNOS−/−mice displayed lower plasma
nitrite concentrations compared to wild
type. Provides evidence that circulating
blood eNOS plays a role in nitrite
homeostasis and BP regulation during
physiological conditions
(Wood et al.,
2013)
Rat Hypertension model. Used
spontaneous hypertensive &
normotensive Wistar Kyoto rats
XOR derived from
RBCs
Potassium nitrite administered
as bolus doses between 1–
30,000 × 10–9 mol/kg
Nitrite decreased BP in a dose-
dependent manner. The effect of nitrite
was greater in spontaneously hyperten-
sive rats compared to normotensive and
was abolished with allopurinol (XOR in-
hibitor). The study showed that this ef-
fect was associated with an increase in
erythrocytic XOR expression but not in
the blood vessel wall
(Ghosh et al.,
2013)
Mouse Assessment of hypoxia vasodilatation
in Mb wild type and deﬁcient mice
Mb Assessed endogenous and exogenous
nitrite. For exogenous studies 1.67 or
16.7 μmol/kg was used
Mb expression in vascular smooth
muscle contributes to nitrite-mediated
hypoxic vasodilatation ex vivo and
in vivo. This effect wasmediated via Mb-
induced activation of NO/sGC/cGMP
pathway
(Totzeck et al.,
2012a)
Rat Normotensive compared to
hypertensive rats. Assessed whether
gastric pH reduced hypotensive effects
– 2 protocols used:
(1) oral (gavage) administration
sodium nitrite (1–45 mg/kg)
compared with
(2) intravenous sodium nitrite
(1–15 mg/kg)
Increased gastric pH caused by
omeprazole reduced the hypotensive
effect of nitrite in both normotensive and
L-NAME-hypertensive rats. The study
concluded that the hypotensive effect of
sodium nitrite was partly due to biocon-
version to NO under acidic conditions of
the stomach
(Pinheiro et al.,
2012)
Mouse Assessed the effects of dietary nitrate
on XOR and eNOS in pulmonary hy-
pertension model
eNOS and XOR Supplementation of drinking water
with either potassium nitrate
(15 mmol/l or 45 mmol/l) or
potassium nitrite (0.6 mmol/l)
Dietary nitrate, but to lesser extent
dietary nitrite, causes pulmonary
dilatation and prevents vascular
remodelling and right ventricular
hypertrophy. These effects were
dependent on eNOS and XOR reduction
of nitrite to NO
(Baliga et al.,
2012)
Ovine Assessed the effects of nitrite on
pulmonary and systemic arterial
vascular resistance in newborn lambs
DeoxyHb Inhalation of sodium nitrite via
nebulizer (0.87 mol/l) compared
to intravascular nitrite infusion
5 mg/kg/h
Inhaled nitrite elicited pulmonary
vasodilatation through NO mediated
mechanism. Intravascular nitrite did not
elicit pulmonary vasodilatation. Inhaled
nitrite produces NO in the airway and
parenchymal lung tissue to mediate va-
sodilatation and this was independent of
deoxyHb in the pulmonary circulation
(Blood et al.,
2011)
Mouse Model of vascular endothelial
dysfunction associated with age using
old (26–28 month) mice compared to
young (4–6 month) mice.
– Supplementation of sodium nitrite
in drinking water (50 mg/l) for
three weeks
Sodium nitrite restored endothelium-
dependent dilatation in old mice via in-
crease in NO bioavailability. Nitrite re-
versed vascular endothelial dysfunction
associated with age
(Sindler et al.,
2011)
Mouse Assessed the effects of nitrite on
vascular Mb
Mb Sodium nitrite Vascular Mb plays an essential role in
nitrite-dependent vasodilatation.
(Ormerod et al.,
2011)
Rat Assessed the role of GTN and sodium
nitrite in the pulmonary vascular bed
ALDH2 and XOR Intravenous injection sodium
nitrite (10–100 μmol/kg)
Administration of GTN or sodium nitrite
caused a decrease in pulmonary and SAP.
Response to GTN or sodium nitrite was
attenuated by cyanamide (ALDH2 inhib-
itor). The effect of sodium nitrite, but not
GTN, was also attenuated by allopurinol
(XOR inhibitor)
(Badejo et al.,
2010)
Rat Assessed the mechanism of nitrite and
RBC-mediated vasodilatation
– Intravenous injection sodium
nitrite 10 μmol/kg
Vasodilatation via nitrite could be
mediated through nitrite enhancement
of ATP release from RBC
(Cao et al.,
2009)
Rabbit Assessed the effect of nitrite on NO-
dependent and independent vasodila-
tation pathways during hypoxic con-
ditions
Aldehyde oxidase,
eNOS, XO
Nitrite During hypoxia, nitrite-induced vasore-
laxation was largely due to nitrite re-
duction by aldehyde oxidase to NO, but
was also partly mediated via the cyclo-
oxygenase pathway. XO or eNOS did not
play a role in this study
(Pinder et al.,
2009)
Rat Effect of carbonic anhydrase on nitrite-
induced vasodilatation during
normoxia and hypoxia
Carbonic anhydrase Sodium nitrite Carbonic anhydrase reacts with nitrite to
produce NO during low pH conditions.
This reaction induced vasorelaxation
during normoxic and hypoxic conditions
(Aamand et al.,
2009)
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Table 1 (continued)
Species Condition/model Nitrite reductase Dose/route/timing administration
of nitrite
Results Reference
Rat Investigated the importance of oral
microﬂora and dietary nitrate in
regulation of BP and gastric mucosal
defence
– Supplementation of drinking water
with either sodium nitrate 10 mM
(~140 mg/kg/day) or sodium nitrite
1 mM (~14 mg/kg/day)
Mouthwash reduced nitrate-reducing
oral bacteria and caused a reduction in
circulating nitrite. BP reduction was ob-
served after nitrate supplementation in
the absence of mouthwash.
Gastroprotective effect of nitrate was re-
duced in rats treated with mouthwash
(Petersson et al.,
2009)
Rat Assessed the role of XOR and ALDH2 in
nitrite-mediated effects on BP in rats
XOR and ALDH2 Intravenous administration of
sodium nitrite
Nitrite decreased mean SAP. The
decreases in mean SAP in response to
sodium nitrite was attenuated by both
XOR and ALDH2 inhibitors. The study
suggested that both XOR and ALDH2
work in parallel to mediate nitrite con-
version to vasoactive NO
(Golwala et al.,
2009)
Rat Assessed the role of XOR in response to
sodium nitrite in the pulmonary vas-
culature
XOR Intravenous injection of sodium
nitrite 10–100 μmol/kg
Intravenous administration of nitrite
decreased pulmonary arterial pressure
and SAP The responses to nitrite was at-
tenuated by allopurinol (XOR inhibitor).
This study suggests that XOR is themajor
enzyme reducing nitrite to vasoactive
NO, and that this mechanism is not
modiﬁed by hypoxia
(Casey et al.,
2009)
Canine Assessed the physiological effects
of sodium nitrite and determined
whether the effect was inﬂuenced
by cell-free plasma Hb during
intravascular hemolysis
Hb Intravenous infusion of sodium
nitrite 27.5 mg/h for 6 h
Nitrite reductase activity of Hb caused an
increased vasodilatory response to
nitrite during low levels of hemolysis
(Minneci et al.,
2008)
Rat Assessed effect of nitrite on BP
in vivo and vasorelaxation in
isolated aorta in vitro
Hb In vivo: intravenous injection of
sodium nitrite (10 μM–2 mM)
In vivo: Sodium nitrite caused a dose
dependent decrease in BP In vitro: Dur-
ing aerobic conditions, XOR, mitochon-
drial electron transport, cytochrome
P450 and NOS inhibitors did not effect
nitrite-mediated vasorelaxation. The
study suggested that heme proteins and/
or sGC pathways are involved in nitrite
mediated effects
(Alzawahra et al.,
2008)
Non-
human
primates
Assessed the physiological and
pharmacological effects of sodium
nitrite on vasodilatory responses
XOR and deoxyHb Sodium nitrite 12.5 μg/kg/min over
24 h for 14 days
Sodium nitrite was a potent vasodilator
at near-physiological concentrations. Ni-
trite was reduced to NO by intravascular
reactionswith deoxyHb. In contrast, XOR
inhibition did not attenuate the nitrite-
induced vasodilatation
(Dejam et al.,
2007)
Rat Assessed effect of Hb oxygen
saturation on vasodilatation
OxyHb/DeoxyHb Sodium nitrite increasing
concentration 0.01 to 1000 μM
Deoxygenation of Hb was associated
with nitrite-dependent vasodilatation
whichwas inhibited byNO scavenger (c-
PTIO) under both normoxic and hypoxic
conditions. In contrast, NO dependent
vasodilatation (via NO donor NONOate)
was inhibited by both oxyHb and
deoxyHb suggesting unique interaction
of nitrite with Hb. This study suggested
that NO homeostasis was regulated by
balance in NO scavenging/generating
activity through oxygen saturation of Hb
(Isbell et al.,
2007)
Rat Effect of nitrite dependent
vasodilatation in hypoxia
(in vitro)
Hb, XO, mitochon-
drial
bc1 complex
Sodium nitrite in cumulative
additions 0.01 to 300 μM
Nitrite induced a concentration
dependent effect on vasodilatation. The
vasoactive effect of nitrite during
hypoxia was attenuated on inhibition of
sGC but was unaffected by inhibition of
xanthine oxidase or the mitochondrial
bc1 complex. In addition, deoxygenation
of Hb did not appear to enhance
vasoactivity of nitrite
(Dalsgaard et al.,
2007)
Rat Hypoxic pulmonary vasoconstriction
in isolated perfused lungs
Hb Lungs perfused with sodium nitrite
buffer increasing concentration (250
nM to 1 mM) with or without RBCs
In isolated perfused lungs, low
concentrations of nitrite inhibited
hypoxic pulmonary vasoconstriction,
possibly due to the release of NO rather
than the direct effect of nitrite on vascu-
lar smooth muscle. However, physiolog-
ical concentrations of RBCs and free Hb
prevented nitrite inhibition of hypoxic
pulmonary vasoconstriction thus raising
doubts for the role of RBCs in nitrite-
mediated vasodilatation in the pulmo-
nary circulation
(Deem et al.,
2007)
(continued on next page)
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Table 1 (continued)
Species Condition/model Nitrite reductase Dose/route/timing administration
of nitrite
Results Reference
Canine In vivo model of acute pulmonary
thromboembolism
– Intravenous infusion of nitrite
(6.75 μmol/kg over 15 min then at
0.28 μmol/kg/min for 120 min)
Infusion of nitrite increased plasma
nitrite levels with a dose-dependent
decrease in pulmonary vascular
resistance index, systemic vascular
resistance index, and MAP
(Dias-Junior
et al., 2006)
Rat and
rabbit
Hypoxic vasodilatation in isolated
thoracic aortas
Hb Sodium nitrite 0.01–1000 μM This study showed that nitrite induced
vasodilatation and supported the role
of RBC Hb to redox regulate nitrite
reductase activity during hypoxia
(Crawford et al.,
2006)
Rat Hypertension Hb-NO complex Acute: sodium nitrite
(1, 3, 10 mg/kg) by oral gavage.
Chronic: sodium nitrite
supplemented in drinking water
(100 mg/l or 1000 mg/l)
Orally administered nitrite is detectable
in the circulation as HbNO. Nitrite
treatment attenuates L-NAME induced
hypertension in a dose-dependent
manner
(Tsuchiya et al.,
2005)
Ovine Assessed inhaled sodium nitrite by
aerosol in hypoxia-induced pulmonary
hypertension in newborn lambs
Hb and iron-
nitrosyl-Hb
Inhaled nebulized sodium nitrite
15 mg/min for 20 min
Pulmonary vasodilatation was elicited
by aerosol nitrite. This was deoxyHb,
pH dependent and associated with
increased blood levels of iron-
nitrosyl-Hb
(Hunter et al.,
2004)
Rat Assessed the role of NO-modiﬁedHb in
isolated rat thoracic aortas
DeoxyHb In vitro sodium nitrite Sodium nitrite was associated with
reduction of nitrite to NO by deoxyHb
during hypoxic conditions
(Cosby et al.,
2003)
Swine In vitro and ex vivo assessment of
nitrite in isolated perfused and
ventilated pig lungs
– Lungs: perfusion of buffer
containing 0.1 and 1 mmol/l nitrite
anions from sodium nitrite
Nitrite anions at physiological
concentrations act as a vasodilator
(Demoncheaux
et al., 2002)
Rat Assessed effect of pH on nitrite-
induced vasorelaxation in rat aorta
– Cumulative addition of sodium
nitrite 0.5 to 1000 μM
Nitrite induced vasorelaxation, which
was enhanced under acidic conditions
and nitrite-derived NO was generated
in a pH-dependent manner. Vasoactivity
of nitrite was greatly reduced by
inhibition of sGC
(Modin et al.,
2001)
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they were given nitrate-supplemented drinking water (10 mmol/l
sodium nitrate) (Petersson et al., 2009). The authors reported a reduc-
tion of nitrate-reducing oral bacteria with a consecutive attenuation of
circulating nitrite levels and the gastroprotective effects of nitrate.
Moreover, nitrite-dependent BP lowering effects of nitrate were
abolished, suggesting oral bacteria play an essential role in the regula-
tion of gastrointestinal and cardiovascular function via the bioactivation
of salivary nitrate (Petersson et al., 2009). Furthermore, Kapil and
colleagues have shown in healthy volunteers that seven days treatment
with an antiseptic mouthwash reduces oral nitrite production by up to
90%, with a concomitant decrease in plasma nitrite levels to 25% of
control values (Kapil et al., 2013).
5. Circulating nitrite and nitrate
5.1. Relationship between plasma nitrite and nitrate
The basal level of nitrite in the plasma of healthy individuals has
been measured, with considerable variation between subjects and
methods used, with values ranging from a range of 50–150 nmol/l to
almost 1000 nmol/l (Gladwin et al., 2000; Lauer et al., 2001;
Kleinbongard et al., 2003; Rassaf et al., 2003; Govoni et al., 2008). The
reason for this variability is not exactly clear but is likely to involve
methodological issues such as ongoing uptake by blood cells during
the centrifugation process. The majority of basal nitrite originates
from the oxidation of NO (Moncada & Higgs, 1993; Rhodes et al.,
1995; Kleinbongard et al., 2003), with the remainder stemming from
the metabolic conversion of dietary nitrate. Ingestion of nitrate causes
a rapid increase in circulating plasmanitratewithin 30min of consump-
tion; the level of plasma nitrate peaks at 3 h with levels remaining ele-
vated for up to 24 h (McKnight et al., 1997; Kapil et al., 2010a).
Elevations in plasma nitrate are followed by a delayed increase in plas-
ma nitrite secondary to bioconversion; nitrite levels rise over 1 to 2 h
and form a plateau between 2 and 6 h after which concentrationsdecline (McKnight et al., 1997; Kapil et al., 2010a). Further research
has demonstrated maximal reduction in BP in humans at 2 to 3 h after
consumption of nitrate, correspondingwith the point of peakplasmani-
trite concentration (Webb et al., 2008b; Petersson et al., 2009). It has
also been suggested that BP reduction by nitrates acts in a dose-
dependent manner (Kapil et al., 2010a), although it is appreciated
now that physiologically, the basal level of nitrite is an important con-
tributor to blood ﬂow regulation.
5.2. The effect of dietary nitrate on circulatory nitrate and nitrite levels
The Mediterranean diet is noted for its high content of vegetables,
fruit and ﬁsh and has been linked to a lower incidence of CVD (Appel
et al., 1997; Joshipura et al., 2001; Lundberg et al., 2006; Grosso et al.,
2014) and diabetes (Salas-Salvado et al., 2014). The volume of vegetable
consumption is notably higher in theMediterraneandiet than theWest-
ern diet; for example in the UK the average vegetable consumption per
day is estimated at 160 g (Meah et al., 1994), while the Mediterranean
diet contains ~550 g of vegetables per day (Trichopoulou et al., 2003).
In terms of vegetable-provided dietary nitrate, the Mediterranean diet
is estimated to contain 400 mg nitrate per day, which is over four
times the amount in a typical Western diet (estimated at 77 mg per
day) (Raat et al., 2009). The Dietary Approaches to Stop Hypertension
(DASH) diet has also been suggested to aid in reduction of CVD, and a
review of current dietary recommendations based on the levels of ben-
eﬁcial dietary nitrate and nitrite has recently been suggested (Hord,
2011).
Numerous studies have demonstrated that intake of nitrate-rich
vegetables can increase the levels of circulating plasma nitrite
(Lundberg et al., 2006; Kapil et al., 2010b; Lidder & Webb, 2012;
Machha & Schechter, 2012). An acute application of sodium (or potassi-
um) nitrate in water or fruit juice or supplementation of the diet with
nitrate has been shown to increase the levels of plasma nitrite
(Lundberg & Govoni, 2004; Larsen et al., 2006; Kapil et al., 2010a). Beet-
root juice has a relatively high nitrate content and is frequently used in
Table 2
Nitrite efﬁcacy in humans and regulation of vasodilatation and blood pressure. A summary of recent studies that have evaluated the efﬁcacy of nitrite as a vasodilator in healthy subjects,
hypertensive and heart failure patients. Acetylcholine (ACh), blood pressure (BP), congestive heart failure (CHF), cyclic guanosinemonophosphate (cGMP), deoxyhemoglobin (deoxyHb),
diastolic blood pressure (DBP), ﬂow-mediated dilatation (FMD), forearm blood ﬂow (FBF), New York Heart Association (NYHA), nitric oxide (NO), nitric oxide synthase (NOS), mean ar-
terial pressure (MAP), red blood cells (RBC), systolic blood pressure (SBP), xanthine oxidoreductase (XOR).
Condition/model Nitrite reductase Dose/route/timing administration
of nitrite
Results Reference
Hypertension model. Grade 1
hypertensive patients
XOR derived from RBCs Dietary nitrate via 250 ml beetroot
juice containing ~3.5 mmol nitrate
Hypertensive patients showed a dose-
dependent effect of plasma nitrite with
decrease in BP and was associated with
increased XOR activity. The study
showed that this effect was associated
with increase in erythrocytic XOR ex-
pression but not in the blood vessel wall
(Ghosh et al., 2013)
CHF patients (NYHA class II–III)
compared to healthy
volunteers. Hemodynamic
assessment of unstressed
forearm venous volume and FBF
– 30 min intravenous infusion
of sodium nitrite
(0.31–7.8 μmol/min) in the
forearm brachial artery
FBF increased markedly in CHF patients
when compared to normal subjects. Un-
stressed forearm venous volume in-
creased in both CHF and normal subjects,
with CHF being hyporesponsive when
compared to healthy subjects. CHF pa-
tients showed accelerated transvascular
clearance of nitrite suggesting increased
conversion to NO in these subjects
(Maher et al., 2013)
Healthy subjects – Dietary nitrate via 200 g beetroot
bread containing 100 g beetroot
(1.1 mmol nitrate)
Beetroot bread increased vasodilatation
and decreased DBP
(Hobbs et al., 2013)
Healthy subjects. Assessment of
inorganic nitrate on endothelial
function by FMD and BP
– Potassium nitrate oral capsules
8 mmol
Inorganic nitrate supplementation had
no effect on endothelial function despite
increases in plasma nitrite levels.
However, inorganic nitrate decreased
SBP and aortic pulse wave velocity, but
had no effect on DBP
(Bahra et al., 2012)
Healthy subjects – Intravenous infusion of sodium
nitrite for 48 h from 4.2 μg/kg/h
to 533.8 μg/kg/h
Nitrite induced a decrease in MAP in
healthy subjects. The maximum tolerat-
ed dose of nitrite was 267 μg/kg/h with
toxicity occurring at 446 μg/kg/h. Con-
cluded that nitritewas safe to infuse for a
prolonged period given the correct dose
(Pluta et al., 2011)
Healthy subjects. Assessment of
dietary nitrate and
supplementation on BP, and sex
differences in response to ni-
trate
– Supplementation with potassium
nitrate (capsules— 4 to 24 mmol)
or beetroot juice 250 ml containing
5.5 mmol nitrate
Nitrate supplementation or beetroot
juice caused an increase in plasma nitrite
and cGMP levels, and was associated
with decreased BP in healthy subjects.
Sex difference in sensitivity to nitrate
was dependent on baseline plasma ni-
trite concentration and BP, whereby
males had lower baseline nitrite levels
and higher BP than females. Following
nitrate supplementation males had sig-
niﬁcantly greater reduction in BP than
the females, thus suggesting differences
in nitrate conversion to nitrite between
the two sexes
(Kapil et al., 2010a)
Healthy subjects. Assessed
acute and chronic
supplementation of nitrate on
BP and exercise
– Dietary nitrate via beetroot juice
500 ml (5.2 mmol nitrate)/day for
15 days
Nitrate supplementation elevated
plasma nitrite concentrations both short
term (2.5 h) and long term (15 days).
Increased plasma nitrite concentration
was associated with decreased BP and
the O2 cost of moderate intensity exer-
cise
(Vanhatalo et al., 2010)
Healthy subjects. Effect of
nitrate from Japanese diet
on BP
– Dietary nitrate provided via
Japanese traditional diet. Estimated
nitrate intake 18.8 mg/kg/day
Consumption of Japanese traditional diet
over a period of ten days increased plas-
ma and salivary levels of both nitrate and
nitrite. Japanese traditional diet was as-
sociated with a decrease in BP in healthy
normotensive subjects
(Sobko et al., 2010)
Healthy subjects. Effect of
low-dose nitrite on hypoxic
pulmonary vasodilatation
– Sodium nitrite infusion into
brachial artery 1 μmol/min for
30 min
During hypoxia sodium nitrite increased
FBF and reduced pulmonary arterial
pressure. No effects were observed dur-
ing normoxia
(Ingram et al., 2010)
Investigated the effects of
sodium nitrite on FBF in pa-
tients with sickle cell disease.
Compared to healthy controls
(Cosby et al., 2003)
– Intravenous infusion of sodium
nitrite (brachial artery:
0.4–40 μmol/min)
Nitrite infusion increased plasma nitrite
in a dose-dependent manner which was
associated with an increase in FBF in
both healthy controls (Cosby et al., 2003)
and patients with sickle cell disease.
However, the response/sensitivity to ni-
trite was reduced in patients with sickle
cell disease
(Mack et al., 2008)
(continued on next page)
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Table 2 (continued)
Condition/model Nitrite reductase Dose/route/timing administration
of nitrite
Results Reference
Healthy subjects. Assessed
effect of dietary nitrate on BP
Dietary nitrate via beetroot
juice 500 ml
(nitrate content ≈ 45.0 mmol/l)
Beetroot juice caused an increase in
plasma nitrite levels and decrease in BP.
This effect was abolished by the
interruption of enterosalivary reduction
of nitrate to nitrite via spitting. The study
demonstrated that the conversion of
nitrate to nitrite is essential for
vasoactivity
(Webb et al., 2008b)
Assessment of FBF and forearm
venous volume during
normoxia and hypoxia in
healthy subjects
– Brachial artery infusion of
sodium nitrite
(40 nmol/min to 7.84 μmol/min)
Nitrite was a potent venodilator during
normoxic and hypoxic conditions. While
nitrite had a modest vasodilatory effect
in the resistance vessels during
normoxia, the effect was potent during
hypoxia
(Maher et al., 2008)
Assessed the physiological and
pharmacological effects of
sodium nitrite on vasodilatory
responses
XOR and deoxyHb 0, 7, 14, 28, 55 and 110 μg/kg/min
5 min each dose
Sodium nitrite was a potent vasodilator
at near-physiological concentrations. Ni-
trite was reduced to NO by intravascular
reactionswith deoxyHb. In contrast, XOR
inhibition did not attenuate the nitrite-
induced vasodilatation
(Dejam et al., 2007)
BP in healthy subjects – 3 day dietary supplementation
with sodium nitrate (0.1 mmol/kg/
day)
Short term dietary nitrate
supplementation increased plasma
nitrite levels and reduced DBP and MAP,
but did not affect SBP in healthy subjects
(Larsen et al., 2006)
Subjects with endothelial
dysfunction compared to
healthy subjects
– Endogenous plasma nitrite Subjects with endothelial dysfunction
displayed lower levels of plasma nitrite
and lower FMD levels than healthy sub-
jects
(Kleinbongard et al., 2003)
Assessed the vasodilatory
properties and bioactivation of
nitrite in forearm (via FBF)
before and during exercise
DeoxyHb Infusion of sodium nitrite 0.36 and
36 μmol/min before and during
exercise
Sodium nitrite induced vasodilatation in
humans and was associated with
reduction of nitrite to NO by deoxyHb
during hypoxic conditions
(Cosby et al., 2003)
Assessed whether changes in
NOS concentrations are reliable
marker for NO production and
whether physiological concen-
tration of nitrite is vasoactive
eNOS Intra-arterial infusion of sodium
nitrite 0.01–36 μmol/min
eNOS stimulation with ACh dose-
dependently increased venous nitrite
levels and this effect was associated by
an increase in FBF. Intra-arterial infusion
of nitrite had no effect on FBF
(Lauer et al., 2001)
310 J.C. Bailey et al. / Pharmacology & Therapeutics 144 (2014) 303–320human studies as a convenient source of nitrate, not least because it is
classiﬁed as ‘food’, simplifying the administrative effort required to
carry out human studies in the UK and other countries. Beetroot juice
consumption in healthy volunteers has been shown to be associated
with an increase in the levels of plasma nitrate (by 16 fold) and nitrite
(by 2 fold) (Webb et al., 2008b). Cermak and colleagues reported a sim-
ilar trend with regard to plasma nitrite levels in trained male cyclists.
Control subjects who consumed 140 ml nitrate-depleted beetroot
juice had plasma nitrite levels of 271 nmol/l, whereas subjects consum-
ing the same volume of beetroot juice (containing 8.7 mmol nitrate)
showed a two-fold higher plasma nitrite level of 532 nmol/l (Cermak
et al., 2012). It has also recently been demonstrated that nitrite/nitrate
handling in humans shows sexual dimorphism: increases in plasma ni-
trate and nitrite levels as well as inhibition of platelet function after
consumption of beetroot juice revealed a clear gender difference
(Velmurugan et al., 2013).
The consumption of dietary nitrate from beetroot juice in healthy
volunteers has been shown byWylie and colleagues to increase plasma
nitrate and nitrite levels in a dose-dependent manner (Wylie et al.,
2013). Volunteers were given beetroot juice containing ~4.2, 8.4 or
16.8 mmol nitrate; the level of circulating nitrate peaked at values of
160 ± 43 μmol/l, 269 ± 92 μmol/l and 581 ± 209 μmol/l, respectively
(all P b 0.05). These corresponded with increases in plasma nitrite to
220 ± 104 nmol/l, 374 ± 173 nmol/l and 653 ± 356 nmol/l (all
P b 0.05) respective to increasing dose (Wylie et al., 2013). Further-
more, Vanhatalo et al. demonstrated that continued beetroot juice con-
sumption over a period of 15 days resulted in sustained elevation of
plasma nitrite levels (Vanhatalo et al., 2010). The authors found that
consumption of beetroot juice containing 5.2 mmol nitrate/daysigniﬁcantly elevated plasma nitrite levels by 35% 2.5 h after ingestion,
25% at 5 days and 46% at 15 days, as discussed further in Section 6.1.
6. Effects of nitrite and nitrate on cardiovascular function
6.1. Effect of dietary nitrates
As discussed in Section 5.2 and depicted in Table 2, several research
groups have demonstrated that ingestion of dietary nitrate (beetroot
juice) in healthy subjects results in increased plasma nitrite concentra-
tion via bioconversion in vivo (Webb et al., 2008b; Kapil et al., 2010a;
Cermak et al., 2012; Velmurugan et al., 2013; Wylie et al., 2013) and
substantial research efforts have focused to investigate the role of this
bioactive nitrite on cardiovascular function (Webb et al., 2008b;
Vanhatalo et al., 2010; Lansley et al., 2011; Bondonno et al., 2012;
Wylie et al., 2013). For instance, Webb and colleagues reported a sub-
stantial reduction in systolic blood pressure (SBP) of 10.4 mm Hg 3 h
after ingestion of beetroot juice, and this effect inversely correlated
with peak increases in plasma nitrite levels (Webb et al., 2008b). In
order to ascertain that nitrite was indeed the carrier of bioactivity that
accounts for the BP change, a complementary spitting study was con-
ducted. The results clearly demonstrated that spitting caused interrup-
tion of the enterosalivary recirculation of dietary nitrate in as much as
it abolished both the rise in plasma nitrite and the decrease in BP
(Webb et al., 2008b).
The consumption of nitrate rich spinach has been shown to decrease
SBP, by 2.7 mmHg, and increase ﬂowmediated dilatation (FMD) of the
brachial artery, by 0.5%, in healthy volunteers (Bondonno et al., 2012).
The response of healthy volunteers to dietary nitrate via beetroot juice
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ship between nitrate load and BP. Ingestion of beetroot juice decreased
SBP and mean arterial pressure in relation to nitrate dose (Wylie et al.,
2013). Decreases in diastolic blood pressure (DBP) were only found
with the higher doses of nitrate in this study. These changes in BP corre-
lated with changes in plasma nitrate and nitrite. The same study also
demonstrated that dietary nitrate can reduce steady-state oxygen up-
take during moderate intensity exercise and increases time to task fail-
ure (Wylie et al., 2013). In agreement with the lack of tolerance
development to the vasodilator effects of nitrite alluded to earlier,
Vanhatalo and co workers have shown that elevated plasma nitrite
levels during subchronic consumption of beetroot juice over a period
of 2 weeks is associated with a sustained decrease in SBP and DBP and
reduced O2 cost of submaximal exercise (Vanhatalo et al., 2010). Simi-
larly, Lansley and colleagues showed that elevated plasma nitrate and
nitrite in healthy competitive male cyclists improved performance in
time trial cycling without alteration of VO2 max by improving exercise
efﬁciency (Lansley et al., 2011). In contrast to these results in ﬁt but un-
trained or moderately trained athletes, dietary nitrate supplementation
has not been demonstrated to have beneﬁcial effects on exercise perfor-
mance or endurance in elite athletes (Peacock et al., 2012; Christensen
et al., 2013).
Overall, the results from these studies suggest that oral nitrate ad-
ministration, particularly via beetroot juice, increases plasma nitrite
levels and produces a moderate vasodilator response in healthy volun-
teers. The effects of dietary nitrate have also been investigated in the
setting of chronic environmental hypoxia and under pathophysiological
conditions (Ghosh et al., 2013; Martin et al., 2013). A double-blind
placebo-controlled study of the effects of beetroot juice on various bodi-
ly functions was carried out in 28 healthy human volunteers, ﬁrst at sea
level and then during 5 days at high altitude (4559 m) (Martin et al.,
2013). The purpose of this study was to investigate whether the beneﬁ-
cial effects of nitrate on mitochondrial efﬁciency observed in some of
the studies described above are maintained or might even be enhanced
under conditions of reduced oxygen availability; if the latter was true
this could be of beneﬁt for critically ill patients suffering from hypox-
emia. Publication of results from this study is eagerly awaited.
In another investigation in patients with grade 1 hypertension it has
been shown that the consumption of beetroot juice can elevate plasma
nitrite levels by 1.5 fold, with the increase being associated with a de-
crease in both SBP and DBP (Ghosh et al., 2013). Grade 1 hypertensives
were classed as those with SBP between 140 and 159mmHg or DBP 90
and 99 mm Hg. Dietary nitrate was consumed by drinking 250 ml of
beetroot juice with nitrate concentration of 13.2 mmol/l. The SBP in
these patients was shown to decrease, with peak mean fall in pressure
occurring between 3 and 6 h after consumption of beetroot juice at
11.2 mm Hg compared to 0.7 mm Hg in controls (Ghosh et al., 2013).
DBPwas also reduced in hypertensive patients who consumed beetroot
juice, with a peakmean fall in pressure of 9.6 mmHg. Similar to healthy
volunteers, in hypertensive patients the decrease in SBP was inversely
correlated with plasma nitrite but not nitrate levels. It is interesting
that compared to healthy volunteers, a lower dose of dietary nitrate is
required to produce a comparable drop in SBP and DBP in hypertensive
patients, perhaps because of these patients' higher BP at baseline
(Ghosh et al., 2013).
Another recent investigation is of interest in the context of discus-
sions about the effects of nitrite and nitrate on BP. In this study,
the skin of 24 healthy human volunteers was exposed for 20 min to
ultraviolet A (UVA) radiation from tanning lamps. During and up to
half an hour after UVA exposure DBP was signiﬁcantly lowered by
~5 mm Hg, and these hemodynamic changes were associated with op-
posite changes in circulating nitrate and nitrite concentrations (Liu
et al., 2014). These light-induced BP changes were independent of
changes in vitamin D levels and suggested translocation of NO bioactiv-
ity from a preformed storage pool in the skin to the circulation, resulting
in an elevation of plasma nitrite at the expense of nitrate. Surprisingly,an acute 10-fold elevation of circulating nitrate levels (from basal con-
centrations of 10.7 μmol/l on a low nitrate diet to 108 μmol/L 1 h after
acute oral ingestion of sodium nitrate) did not alter the hemodynamic
effects of UVA light. Thus, in addition to the bioactivation of nitrate to ni-
trite via oral commensal bacteria, another endogenous pool of nitrate
(or a closely related NO species that can give rise to nitrite) appears to
exist in human skin that may contribute to BP regulation in response
to exposure of the body to UVA/sunlight.
These studies built on earlier investigations on the effects of light on
vascular tone of isolated rabbit aortic strips in organ baths (Furchgott
et al., 1961), a phenomenon known as ‘photorelaxation’. In those stud-
ies, addition of sodium nitrite to the organ bath potentiated light-
induced vasorelaxation in an endothelium-independent manner
(Matsunaga & Furchgott, 1989). This effect of nitrite was potentiated
by the presence of superoxide dismutase or other O2− scavengers
(Matsunaga & Furchgott, 1989, 1991), demonstrating the importance
of the balance between NO and O2−. Later studies in rat aortic rings
showed that the release of NO from vascular storage forms comprising
S-nitrosothiols and nitrite account for the phenomenon of
photorelaxation (Rodriguez et al., 2003).
6.2. Nitrite-mediated vasodilatation in
physiological and pathophysiological conditions
6.2.1. Animal studies
The use of nitrite as a BP lowering agent dates back to the beginning
of the last century (Butler & Feelisch, 2008). In 1953, the ability of nitrite
to act as a vasodilator was ﬁrst demonstrated by Furchgott and
Bhadrakom who showed that administration of sodium nitrite to pre-
contracted rabbit aortic strips in vitro induced vasorelaxation
(Furchgott & Bhadrakom, 1953). In subsequent studies 200 μmol/l ni-
trite was shown to relax rat aorta in vitro under normoxic conditions,
with a reduction to 40 μmol/l required under hypoxia (Modin et al.,
2001).While in a caninemodel under normoxic conditions aortic relax-
ation has been shown to occur with administration of nitrite at levels
between 100 and 1000 μmol/l (Arai, 2006). In more recent work, high
micromolar to millimolar pharmacological concentrations of exoge-
nously administered nitrite have been demonstrated to relax pre-
constricted isolated blood vessels (Maher et al., 2008; Ormerod et al.,
2011). Thus, when studied using isolated vascular preparations nitrite
is far less potent vasodilator than NO itself. In very early work by
Reichert and Mitchell (1880), potassium nitrite was found to exert a
dose-dependent effect on pulse (at the time these experiments were
conducted routine BP measurement was not yet part of clinical practice
and only possible using somewhat cumbersome invasive methods
(Booth, 1977); thus, pulse rate was used as a proxy for systemic effects
on the circulation). Inman, 2 grains of potassiumnitrite showed little ef-
fect on pulse (1 grain is a unit ofmass equal to ~65mg; 2 grains translate
into a dose of ~2 mg/kg). When the dose was increased to 6 grains, the
pulse (measured 40 min after nitrite administration) was increased by
~30 beats per minute; this was associated with throbbing vessels and
warmth to the face. Ten grains of potassium nitrite increased pulse to
an even greater extent within 25 min, concurrent with ﬂushed face
and hands and a throbbing headache. These observations are consistent
with systemic and peripheral vasodilatation. The same authors also re-
ported the effects of potassium nitrite on arterial BP in animals. In ex-
perimental rabbits, cats and dogs, large doses of potassium nitrite (0.2
g in rabbits and cats and 0.5–1.0 g in dogs) caused an immediate and
continual decrease in BP to zero. However, a smaller dose (0.08 g) in-
creased BP within 30 s after administration, which was followed by a
decline in pressure; further administration of nitrite caused a similar
pattern of transient increase followed by a large, sustained fall in
blood pressure (Reichert & Mitchell, 1880). A similar dose-dependent
effect of nitrite on BP has been reported more recently by Feelisch and
colleagues (Bryan et al., 2005). Intraperitoneally administered low
doses (0.1 mg/kg) of sodium nitrite in rats caused a small, non-
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doses (1.0 and 10 mg/kg) decreased BP by amaximum of 5% and 27% of
controls, respectively. Since no direct vasoconstrictor effects to nitrite
have been observed in vitro, these studies suggest that in vivo nitrite
has a dual effect on the vasculature, acting as a vasodilator at higher
doses while eliciting a transient pressor effect at lower to intermediate
doses; the latter may be secondary to functional interaction with
other vasoactive factors.
In an in vivo study in Wistar rats, it has been demonstrated that ad-
ministration of either infused sodium nitrite, or potassium nitrite sup-
plemented in the drinking water is associated with a decrease in MAP
in both anaesthetized and freely moving rats (Vleeming et al., 1997).
In a mouse model of ischemic (hypoxic) hind-limb, hypertensive mice
showed a signiﬁcantly decreased blood ﬂow compared to sham operat-
ed mice, and blood ﬂow could be recovered in both hypertensive and
normotensive mice when treated with sodium nitrite compared to
non-treatedmice. Inhibition of XOR prevented this recovery, suggesting
a role for XOR-mediated reduction of nitrite to NO in blood ﬂow under
these conditions, as suggested in in vitro studies (Li et al., 2003; Amin
et al., 2012). Hypertensive mice also demonstrated a decrease in
cGMP levels compared to control mice in the hind limb (Amin et al.,
2012). However, treatment with sodium nitrite was found to signiﬁ-
cantly enhance cGMP levels; thus in this study, it was suggested that so-
dium nitrite could be used as a therapy for full recovery of blood ﬂow.
Table 1 summarises studies to date investigating the role of nitrite on
vasodilatation and BP in animal models.
6.2.2. Translational studies in man
The vasodilatory effects of nitrite infusion were later translated to
healthy human volunteers. In 2003, Cosby and colleagues showed that
sodium nitrite vasodilates the forearm vasculature when infused into
the brachial artery (Cosby et al., 2003). Initially, a high dose of
36 μmol/min (2.4 mg/min), resulting in an approximate intravascular
nitrite concentration of 200 μmol/l, was tested and found to signiﬁcantly
increase FBF bothwith andwithout NOS inhibition byN-methylarginine
(n=10, P b 0.01). FBF increased further on forearmexercise during con-
tinued nitrite infusion, despite relative reduction in nitrite concentration
due to increased blood ﬂow. Cosby and colleagues went on to test a
“near-physiological” dose of 400 nmol/min (27.6 μg/min), which signif-
icantly increased FBF from 3.5 ± 0.2 to 4.5 ± 0.3 ml/min/100 ml tissue
(n = 10, P b 0.006) at rest, and to a greater extent on exercise (Cosby
et al., 2003). The authors concluded that basal levels of nitrite are capa-
ble of inﬂuencing resting vascular tone and subserving hypoxic vasodila-
tation. In subsequent studies, the same group extended their previous
observations with systemic nitrite. A lower dose of sodium nitrite,
resulting in a plasma concentration of just 350 nmol/l, was found to
cause a signiﬁcant drop in BP in healthy volunteers. In addition, the au-
thors showed a dose-dependent increase in sodiumnitrite infusion (0 to
110 μg/kg/min) increased FBF from 2.8 to 12.3 ml/min/100 ml tissue
(Dejam et al., 2007).
In support of an enhanced role of nitrite during hypoxia, the effects
of sodium nitrite infusion during normoxia and hypoxia, respectively
in healthy volunteers were investigated by our group (Maher et al.,
2008). Sodium nitrite was infused into the forearm brachial artery at
doses from 40 nmol/min to 7.84 μmol/min (Maher et al., 2008). Under
normoxic conditions, large decreases in forearm venous tone were
found at doses between 784 nmol/min and 7.84 μmol/min, with peak
venodilatation of 35.8% (±7.5% P b 0.005) occurring at the highest in-
fused dose of 7.84 μmol/min. The forearm blood ﬂow ratio (FBF-R: FBF
corrected for control arm) was increased during the two highest doses
of nitrite infusion at 3.14 μmol/min and 7.84 μmol/min, increasing
from a baseline of 1.0 to 1.8 and 1.6 respectively (Maher et al., 2008).
Under hypoxic conditions, FBF-R was enhanced following infusion of
7.84 μmol/min and FBF-R signiﬁcantly increased compared to the
same dose under normoxic conditions (P b 0.05). We concluded that
under normoxic conditions, nitrite was a potent vasodilator ofcapacitance vessels but only amodest dilator of resistance vessels (com-
pared with other vasodilating agents), while under hypoxic conditions
administration of exogenous sodium nitrite has a substantial relaxation
effect on resistance vessels. This may be due to the relatively low PO2 in
the capacitance bed compared to resistance vessels under physiological
conditions; thus the effect of nitrite on capacitance vessels will bemore
pronounced in normoxia, whereas in hypoxia nitrite demonstrates a
greater effect on the resistance vessels due to the decrease in PO2 ap-
proaching levels (previously seen but not markedly enhanced) in the
capacitance vasculature. This study thus demonstrated that oxygen ten-
sion plays an essential role in determining the vasodilatory response to
nitrite (Maher et al., 2008), although it does not exclude the involve-
ment of other contributing factors. Table 2 summarises the recent stud-
ies that have investigated the efﬁcacy and potential mechanisms of
nitrite-mediated vasorelaxation and BP reduction in healthy and patho-
physiological conditions, such as patients with hypertension or heart
failure.
There are noticeable discrepancies between studies regarding to the
dose of nitrite and increased blood ﬂow in normoxia (Lauer et al., 2001;
Cosby et al., 2003; Maher et al., 2008). It has been proposed that in
normoxia, both acetylcholine (Larrousse et al., 2006) and bradykinin
(Wotherspoon et al., 2005) are more effective vasodilators, inducing in-
crease in blood ﬂow by three to four fold, but that in hypoxia it appears
that nitrite plays a dominant role. This would suggest that different
pathways exist to confer vasodilatation during normoxia and hypoxia
and the differing conversion of nitrite to NO under varying oxygen ten-
sions is thus believed to be an important feature integral to hypoxic
signalling.
The results on nitrite on human FBF under normoxic conditions
(Cosby et al., 2003) are in stark contrast to earlier ﬁndings by Lauer
et al. (Lauer et al., 2001), claiming that nitrite had no direct vasodilator
effect when intra-arterially infused, for oneminute, at a rate identical to
that used in the Cosby study. An explanation for this discrepancy is
discussed in Section 7 (mechanisms of nitrite-mediated vasodilatation).
With regard to nitrite administration in pathophysiological condi-
tions, a study comparing the intraarterial effects of nitrite administra-
tion in healthy volunteers with congestive heart failure (CHF) patients
highlighted differing effects of nitrite administration between the two
groups (Maher et al., 2013), with evidence of hyperresponsiveness in
forearm resistance vessels in the latter (Maher et al., 2013). In contrast
there was reduced venodilation in the heart failure patients, however
at any given nitrite infusion dose the venous levels of plasma nitrite
were lower in the heart failure patients vs controls indicating increased
clearance across the forearm vascular bed and possibly explaining the
apparent venous hyporesponsiveness (Maher et al., 2013). The results
from these studies in patients with CVD highlights complications
which may arise when translating results from both animal models
and healthy human models into clinical settings, and more research in
the presence of particular disease statesmay be required to fully under-
stand how nitrite, and indeed other forms of therapy, can be applied for
maximum patient beneﬁt and improved clinical outcome.6.3. Role of nitrite at different oxygen tensions
Studies have shown that the level of nitrite in plasma appears with
an apparent arteriovenous gradient, showing greater vasodilatation ac-
tivity in the capacitance vessels under normoxic conditions and in the
resistance vessels under hypoxic conditions (Maher et al., 2008, 2013).
This effect has also been observed in studies of human FBF,most notably
during exercise (Gladwin et al., 2000; Cosby et al., 2003). It has been
suggested that this gradient may be due to consumption of nitrite and
NO during transit along the vascular tree (Gladwin et al., 2000; Cosby
et al., 2003); the nitrite reductase activity of deoxyhemoglobin
(deoxyHb) in particular is suggested to play a role in nitrite–NO forma-
tion as described below.
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this area is hemoglobin (Hb). Oxyhemoglobin (oxyHb) and deoxyHb
are known as potent NO scavengers (Joshi et al., 2002; Isbell et al.,
2007), and have been shown to regulate the effects of NO (Grifﬁth
et al., 1984). However, only oxyHb chemically reacts with NO to form
nitrate, deoxyHb binds it to form nitrosylHb. The balance between the
different states of oxygen saturation in Hb has been suggested to con-
tribute to the gradient effect between arterial and venous systems,
with deoxygenation of the hememoiety suggested to express reductase
activity with maximal efﬁciency around the p50, i.e. the oxygen partial
pressure at which 50% of the hemoglobin is oxygenated (Huang et al.,
2005; Crawford et al., 2006; Feelisch et al., 2008; Gladwin &
Kim-Shapiro, 2008). It has been suggested that Hb acts as a nitrite re-
ductase in the blood, with red blood cells (RBC) representing the princi-
ple source of Hb and a carrier of nitrite (Dejam et al., 2005). Hb can
interact with blood nitrite via a redox process determined through
both the heme redox potential and oxygen saturation of Hb (Shiva
et al., 2011). A particular balance of oxyHb to deoxyHb is required for
optimal reduction of nitrite to NO, peaking around the p50 value. The
NO produced may then interact with mitochondrial cytochrome c oxi-
dase which contains a binuclear centre to which oxygen ordinarily
binds in the mitochondrial respiratory chain. However, upon cyto-
chrome c oxidase–NO binding, oxygen binding becomes inhibited, and
mitochondrial respiration is reduced (Shiva et al., 2011). During hypox-
ia, NO-mediated inhibition of mitochondrial respiration is enhanced.
This processmay aid the extension of oxygen gradients in tissues ensur-
ing oxygen delivery to a greater tissue area, regulating mitochondrial
ROS generation and the action of Hypoxia Inducible Factor 1-α (Hagen
et al., 2003). Physiologically, the vasodilatory action of Hb reduction of
nitrite to NO is suggested to mediate the cGMP-dependent pathway of
vasodilatation in hypoxia (Cosby et al., 2003; Huang et al., 2005;
Jeffers et al., 2005; Crawford et al., 2006).
The effect of oxygen tension on nitrite metabolism has also been in-
vestigated in animal experimental models. RBC homogenates showed
the expected behaviour in as much as NO production from nitrite was
found to be maximal around the p50 value of Hb (Feelisch et al.,
2008). In contrast, in rat tissue homogenates the in vitro reduction of ni-
trite to NO was shown to be limited under normoxic conditions, while
nitrite to NO conversion progressively increased at lower oxygen con-
centrations in all organs, including vascular tissue (Feelisch et al.,
2008). This metabolic activity was associated with an increase in the
formation of nitrosated and nitrosylated products in vivo. The formation
of NO from nitrite was found to be largely enzymatic in nature as it was
sensitive to heat inactivation and blockage of thiol groups (Feelisch
et al., 2008), supporting earlier studies implicating heme and thiol-
containing reductases in this process (Bryan et al., 2005). Data from a
more recent in vivo study carried out in rats suggest that acute hypoxic
vasodilatation is largelymediated by NOmetabolites rather than by free
NO from Hb-mediated nitrite reduction (Umbrello et al., 2014).
The step-wise reduction of nitrate to nitrite and nitrite to NO has
been demonstrated under anoxic conditions in vitro with a role for
nitrate/nitrite reductase xanthine oxidase (XO) (Li et al., 2003). The
authors of this study also found that nitrite and NO production was
pH-dependent with maximum observable NO production at pH 5.0,
suggesting that XO reduces nitrate to nitrite and NO under acidic condi-
tions, as associated with CVD (Li et al., 2003).
7. Mechanisms of nitrite-mediated vasodilatation
Much of our current understanding about nitrite's mode of action as
a vasodilator is based on animal experimental work and observed asso-
ciations of changes in circulating plasma concentrations and blood ﬂow
and/or pressure at pharmacological doses; other pieces of information
are derived from in vitro studies with isolated proteins or cultured
cells. Considerably less information is available on themechanismof va-
sodilatation by nitrite in human tissue and the role, if any, ofendogenous nitrite for human physiology. The fact that nitrite can
relax isolated segments of precontracted vascular tissue in organ baths
does not necessarily mean that it is involved in the regulation of BP.
Part of the paucity of mechanistic information is due to the fact that
monitoring the rather low concentrations of endogenous nitrite re-
quires speciﬁc analytical equipment such asHPLC or gas phase chemilu-
minescence, which is not available in every laboratory; another reason
is that our current understanding of basic processes including nitrite/ni-
trate uptake, processing and excretion at the cellular and whole organ-
ism level is incomplete. Moreover, while biochemically interesting in
principle some in vitro ﬁndings obtained with high nitrite concentra-
tions under complete anoxia are likely to be of limited relevance to
physiology. The lack of pharmacological tools such as speciﬁc ‘nitrite
scavengers’ is also a limiting factor. The extrapolation of animal experi-
mental data to human physiology requires particular care — not every-
thing that looks promising in the animal experimental setting is
ultimately going to work in humans.
It is important to acknowledge that no ‘nitrite receptor’ has yet been
described; thus, there is no mechanistic basis for a direct coupling of a
nitrite recognition site to a down-stream signalling event in smooth
muscle to trigger vasodilatation. Therefore, the vasodilator effects of
nitrite are not, at least at present, known to be a consequence of interac-
tion with a speciﬁc receptor in vascular tissue; with no ‘nitrite receptor’
as target, there is likely no simple concentration–response relationship
for its biological effect either. Although it cannot be excluded at present
that nitritemay affect processes coupled to the transport of other anions
in the vasculature (a process that could conceivably affect vascular
tone), all evidence available to this date suggests that nitrite has to be
metabolized to NO, or an NO-like species, in order to exert a biological
effect. This process appears to require the presence of a sulfhydryl
group and a heme moiety (Bryan et al., 2005). There is no agreement
in the literature as to whether nitrite is metabolized intracellularly or
bioactivated in the extracellular space. Nitrite may require prior entry
to the tissue ﬁrst before it can act as a vasodilator. In this case, the plas-
ma/tissue concentration gradient would seem to be important, but
transport may well be via a carrier-facilitated uptake, with competition
by other anions— little is known about any of this. Once inside the vas-
cular tissue, nitrite may interact with one of the enzymes described
below to become reduced to NO (or N2O3) and/or become
biotransformed to nitroso and/or nitrosyl species before being able to
interact with sGC to produce cGMP. However, nitrite transport into
cells may not be required in all cases as it has recently been shown
that nitrite reduction can also occur through red blood cell (or endothe-
lial cell) nitrite reductases such as XOR (Ghosh et al., 2013) tomediate a
vasodilatory response.
A surprisingly large number of different proteins have been identi-
ﬁed that can reduce nitrite to NO in vitro, and detailed recent reviews
on this topic are available (van Faassen et al., 2009; Kapil et al., 2010b;
Lundberg &Weitzberg, 2010; Kim-Shapiro & Gladwin, 2013). However,
there is neither agreement in the literature as to which of these poten-
tial nitrite bioactivation processes are the most relevant for vasodilata-
tion (or any other biological process), nor do we understand the
reason for this particularly high degree of redundancy. In principle,
the processes involved are chemical/non-enzymatic or enzymatic,
with different pH optima for nitrite reduction depending on the nature
of the proteins involved. Many of the enzymatic pathways demand
rather low concentrations of oxygen to reduce nitrite efﬁciently. In
fact, oxygen appears to be a highly effective inhibitor of tissue ‘nitrite re-
ductase’ activity (Feelisch et al., 2008). Thus, hypoxia does not ‘stimu-
late’ nitrite reduction, it is rather that lower levels of oxygen result in
less inhibition.
The simplest chemical pathway of NO generation from nitrite in-
volves disproportionation of the corresponding acid, HNO2. This path-
way is probably not of much relevance for nitrite bioactivation in
vascular tissue, unless it is rendered hypoxic for a prolonged period of
time. Both Hb (Basu et al., 2007) and carbonic anhydrase (Aamand
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anhydrase activity, a reaction in the course of which N2O3 is formed,
eventually giving rise to NO and NO2. While the former could theoreti-
cally provide a convenient way of exporting nitrite-derived NO from
RBCs under hypoxic conditions, recent animal experimental results sug-
gest that the majority of hypoxic vasodilatation is not mediated by Hb-
mediated nitrite reduction (Umbrello et al., 2014). The nitrite reductase
activity of carbonic anhydrase appears to be linked to the coupling of ce-
rebral blood ﬂow and metabolic activity in response to visual stimula-
tion (Aamand et al., 1985, 2009).
It would perhaps be desirable to group proteins according to the
mechanism involved in nitrite reduction, but this is not known for all
proteins to date. Moreover, a single protein may employ several differ-
ent pathways to reduce nitrite to NO; in the case of Hb and myoglobin
(Mb) these have been proposed to include R-state catalysis, oxidative
denitrosylation (of the intermediate NO-heme product formed), and
the above nitrite anhydrase reaction (Gladwin et al., 2009). Alternative-
ly, a thiol group in Hb may become nitrosated during deoxygenation/
reoxygenation, by a mechanism involving NO-heme formation from ni-
trite, to form a nitrosothiol (SNO-Hb) which may serve as NO-carrier
(Angelo et al., 2006), or that nitrite is reduced by the eNOS expressed
in RBCs (Cortese-Krott et al., 2012) under some conditions. Thus, even
for some of the most extensively studied proteins the precise mecha-
nisms involved remain unclear. As a result, proteins are typically
categorised according to the principle reaction they are known to catal-
yse (which may not always match with the mechanism involved in ni-
trite bioactivation, but that is another matter), or the prosthetic group
they carry. According to this principle, the proteins involved in nitrite
reduction can be divided into two broad groups: heme-based proteins
andmolybdopterin-based oxidoreductases. The two best studied exam-
ples of the former are Hb and Mb, and both have been claimed to play
major roles in nitrite bioactivation (Shiva et al., 2007a; Totzeck et al.,
2012b; Kim-Shapiro & Gladwin, 2013), in particular under hypoxic con-
ditions (Crawford et al., 2006; Hendgen-Cotta et al., 2014). Less well
studied members of this group include neuroglobin and cytoglobin,sGC GTP
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Fig. 1. The role of nitrite-derived nitric oxide in the vasculature. During normoxia, L-arginine is
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The most recent member of the heme-based nitrite reductases is
cystathionine beta-synthase (CBS) (Gherasim et al., 2014), a key en-
zyme of the transsulfuration pathway involved in homocysteinemetab-
olism, glutathione production, and formation of hydrogen sulﬁde (H2S).
As with other heme-based reductases, NO-heme formation leads to
autoinhibition of the enzyme, representing an interesting new facet of
the NO/H2S cross-talk. Members of the molybdopterin-based oxidore-
ductases shown to reduce nitrite to NO involve XO (Cantu-Medellin &
Kelley, 2013), aldehyde oxidase (Li et al., 2008), and sulﬁte oxidase
(Wang et al., 2011). Many of the above proteins have been studied in
relative isolation; their importance in mediating the vasorelaxant re-
sponse to nitrite has been assessed using pharmacological inhibitors
(of varying speciﬁcity) and, in some cases, knockout mice. Yet most pa-
pers are limited to the investigation of one speciﬁc pathway, and read-
ing the literature one could easily get the impression that they are all
equally important, or solely responsible for the effects of nitrite under
some conditions. Fig. 1 illustrates the nitrite-derived NO signalling in
the vascular system.
Let us now revisit the discrepancy between the in vivo results pre-
sented by the groups of Lauer et al. and Cosby et al. mentioned in
Section 6.2.2. Why did apparently identical solutions of sodium nitrite
in saline produce no vasodilatation whatsoever in one case (Lauer
et al., 2001) and marked increases in FBF in the other (Cosby et al.,
2003) Notwithstanding minor differences in blood ﬂow at baseline, in-
travascular nitrite concentrations achievedmust have been of compara-
blemagnitude. The explanationmay be linked to differences in infusion
times (and thus total amounts of nitrite delivered). If the same concen-
tration of a nitrite stock solution is infused at the same rate into the vas-
culature then the total amount of bioactive drug (nitrite) scaleswith the
duration of infusion. In the earlier studies by Lauer et al. infusions were
limited to 1 min (during which time no changes in blood ﬂowwere ob-
served, consistent with a lack of direct vasodilator effect of nitrite)
whereas in the Cosby study infusions continued for as long as 5 min.vasodilataon 
-
Hypoxia 
NO
urces
hypoxic vasodilatation 
metabolized in endothelial cells via nitric oxide synthase (NOS) to nitric oxide (NO) to in-
ogenous substance produced via the oxidation of NO (principally by cytochrome c in cells
multiple nitrite reductases, including deoxyhemoglobin, myoglobin, xanthine oxidoreduc-
osphate); sGC (soluble guanylyl cyclase); NO3− (nitrate).
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temic circulation, gaining access to tissues and blood cells; if the rate of
administration exceeds that of elimination, nitrite and its metabolic
products (including nitroso and nitrosyl species) begin to accumulate
in the vasculature and relaxation ensues. A number of animal experi-
mental results (Bryan et al., 2004; Nagasaka et al., 2008; Perlman
et al., 2009) indicate that plasma concentrations of nitrite are uncoupled
from those in tissues, suggesting the involvement of additional steps
that regulate circulating nitrite concentrations. Thus, short-term infu-
sions of nitrite may differ in effects on pressure and ﬂow from those of
longer lasting infusions, and total amounts of nitrite delivered may be
as important as local concentrations achieved. If thiswas true, in vivo ni-
trite administration regimes might better be compared on the basis of
cumulative amounts administered rather than circulating concentra-
tions measured — time will tell.
While initial efforts focussed on the identiﬁcation of potential nitrite
bioactivation pathways (often under very speciﬁc reaction conditions
with exclusion of oxygen), manymore ‘leads’ emerged than anticipated
and likely in operation under physiological conditions. There is a grow-
ing appreciation that reduction of nitrite to NOmay bemediated by dif-
ferent pathways under different physiological conditions and that the
effects of nitrite are sometimes mediated by metabolites other than
NO. Moreover, most of the known chemistries proposed to be involved
in these processes are rather slow, questioning their overall relevance
for physiological regulation. Ultimately, conﬁrmation for the involve-
ment of candidate pathways of bioactivation will require in vivo exper-
imentation. To this end, Hendgen-Cotta et al. (2014) have recently
demonstrated a role for Mb in nitrite-mediated vasodilatation under
hypoxic conditions. In addition, there is increasing evidence that nitrite
reduction may occur via blood borne protein mediated mechanisms
such as RBC eNOS, as demonstrated by Webb et al. (2008a) and Wood
et al. (2013), as opposed to or in addition to the currently favoured vas-
cular tissue-derived NO. Also of interest is recent work by Umbrello
et al. (2014)who have demonstrated that short-term hypoxic vasodila-
tationmay bemediated by bioactive NOmetabolites rather than by free
NO. These recent ﬁndings are of great interest in terms of the perceived
“physiology” of nitrite but require further substantiation and indepen-
dent conﬁrmation by other groups. The above observations do not ex-
clude the possibility that nitrite bioactivation occurs through as yet
unknown enzymatic or chemical mechanisms. There is also much to
be considered physiologically in terms of cross-talk between different
enzymatic pathways, such as regulation of activity, which will impact
on the effects of nitrite and rate of NO/metabolite production and clear-
ance, and even other chemical entities (carbonmonoxide and hydrogen
sulﬁde, for example) much of which has yet to be discovered in vivo.
8. Potential therapeutic role of nitrite in acute heart failure
Acute emergence or deterioration of heart failure, with or without
the associated development of acute pulmonary edema and the poten-
tial need for assisted ventilation, remains a frequent cause of hospital
admission with associated morbidity and mortality. Furthermore,
there is currently no consensus as to the optimal management of AHF,
despite emergence of a large number of potential forms of pharmaco-
therapy. Many patients with AHF have pre-existent impairment of left
ventricular systolic function, and decompensation may reﬂect intercur-
rent infection, onset of tachyarrhythmias, recurrent myocardial ische-
mia and/or poor compliance with prescribed therapy.
Traditionally, AHF has been treatedwith therapeutic regimens based
on the use of diuretics, but it has emerged over the past 20 years that a
therapeutic approach centred on the intravenous administration of NO
donors to all patients with associated pulmonary edema, together
with inclusion of NOdonors in the treatment of patientswith less severe
hemodynamic decompensation, may have substantial advantages
(Beltrame et al., 1998; Cotter et al., 1998). On this basis, intravenous in-
fusion of organic nitrates such as GTN or isosorbide dinitrate iscommonly utilized as a component of therapy for AHF with pulmonary
edema.
While organic nitrate infusions are generally helpful in the immedi-
ate treatment of such patients, they impose a number of difﬁculties.
Firstly, organic nitrates such as GTN are absorbed by the plastics mate-
rial of common intravenous infusion set (bags and infusion tubing)
(Cawello & Bonn, 1983; Hansen & Spillum, 1991). Hence, unless
specialised infusion apparatus is used, it is uncertain whether patients
are receiving appropriate GTN infusion rates. Secondly, all organic ni-
trates are potentially prone to the development of nitrate tolerance dur-
ing long-term therapy: this is manifest as progressive attenuation of
hemodynamic and anti-aggregatory responses to the administered ni-
trate, with cross-tolerance to other organic nitrates. While some inves-
tigators have suggested that nitrate tolerance is also associated with
worsening of endothelial dysfunction and attenuation of responsive-
ness to endogenous NO (that is, cross-tolerance to endothelial NO),
overall evidence is more consistent with the concept that nitrate toler-
ance is engendered primarily by failure of enzymatic release of NO
fromorganic nitrates (Sage et al., 2000). As the probability of emergence
of nitrate tolerance is determined essentially by the combination of in-
fusion rate and duration of exposure (Henry et al., 1989), this imposes
the need to utilize organic nitrate infusions brieﬂy and with the lowest
possible infusion rates.
On the other hand, patients with heart failure, whether acute or
chronic, display tissue resistance to the effects of NO (for review see
(Chirkov & Horowitz, 2007)), related primarily to dysfunction of sGC
and “scavenging” of NO by O2−. Hence low organic nitrate infusion
ratesmay not achieve ideal hemodynamic responses. Resorting to inter-
mittent dosing regimes, as sometimes used for antianginal treatment, is
impractical for AHF as it bears the risk of inappropriate therapeutic cov-
erage during drug-free intervals.
Infusion of nitrite as ameans of treatment for AHFoffers a theoretical
means of circumventing many of the problems associated with organic
nitrate infusion. The relative selectivity for the (hypoxic) venous capac-
itance vessels and pulmonary vasculature would be an attractive proﬁle
in the management of decompensated heart failure. Furthermore the
apparent lack of tolerance (Haas et al., 1999; Dejam et al., 2007)
would be an additional advantage over organic nitrates (Sage et al.,
2000). However sustained high dose nitrite infusion can cause methe-
moglobinemia and hemolysis (Pluta et al., 2011). To date there have
been no large scale studies of nitrite infusion in heart failure.
9. Potential toxicity of nitrite and nitrate
Although the role of nitrite and nitrate in cardiovascular health is be-
coming increasingly apparent, the ingestion of these anions has also
been linked to health concerns. There is an abundance of literature on
the subject, so we only provide a few pointers for balance here. Dietary
nitrate and nitrite can form N-nitrosamines, and countless animal stud-
ies have documented low-molecular weight N-nitrosamines to be
carcinogenic in numerous organ systems when ingested orally over
prolonged periods (Archer, 1989; Mirvish, 1995; Tricker, 1997). In
humans, the role of dietary intake of N-nitrosamine compounds and
their precursors in the development of cancer is of ongoing interest,
but relies largely on observed associations between the intake of certain
food classes and cancer risk/death; inmany cases, nitrite and nitrate (or
preformed N-nitroso compound) intakes were not quantiﬁed but esti-
mated using food frequency questionnaires (considering the level of
geographical and seasonal variations in nitrate content alone this is
not without problems). Some more recent meta-analyses and careful
re-assessments of cancer risks and dietary habits in larger cohorts ﬁnd
no association between nitrite and/or nitrate intake and cancer devel-
opment, but risks may vary depending on cancer types and organs in-
volved. Most likely, matters are much more complicated than hitherto
assumed, with environmental and life-style related factors playing im-
portant modulatory roles. One very recent study (Dellavalle et al.,
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of increased nitrate intake but is secondary to reduced antioxidant
levels (vitamin C, for example, can inhibit nitrosation). Teleologically,
it is difﬁcult to see why moderate intake levels of nitrite and nitrate
would be linked to cancer development as they occur endogenously in
astonishing concentrations in some compartments (e.g. in saliva) and
thus are part of our normal body physiology.
Another concern about nitrate ismethemoglobinemia. Bacteria in the
mouth and gut convert nitrate into nitrite, and nitrite reacts with Hb to
produce methemoglobin, which is no longer able to transport and re-
lease oxygen effectively to tissues. Most cases of methemoglobinemia
were reported in the 1940s where methemoglobinemia or “baby blue
syndrome” was seen in infants fed formula with nitrate contaminated
well-water (Powlson et al., 2008). It was later suggested that methemo-
globinemiawas not caused bynitrate but by fecal bacteria contamination
in the well-water or bacterial nitrate reduction in vivo that may have
caused the intestinal infection, and this may have been responsible for
the nitrate-induced methemoglobinemia in the infants (Hanukoglu &
Danon, 1996; Ward et al., 2005). Of interest, nitrate was used in very
high doses (often for weeks) at the beginning of the last century as a di-
uretic (Butler & Feelisch, 2008). Recent studies by Pluta et al. (2011) have
investigated the safety and feasibility of long-term intravenous infusion
of sodium nitrite in healthy subjects. The authors demonstrated that
acute intravenous infusion of sodium nitrite was tolerated up to a maxi-
mum dose at 267 μg/kg/h, and that the dose-limiting toxicity was
reached at 446 μg/kg/h. Toxicity included a transient asymptomatic de-
crease of MAP and an increase of methemoglobin (above 5%). Overall,
the authors suggested that nitrite could be ‘safely infused intravenously
at deﬁned concentrations for prolonged intervals’.
Finally, although there are reports to suggest that nitrate and nitrite
are harmful when ingested in excess, the same is true for about every
other substance essential to mammalian life including glucose, fat and
oxygen. It is important to establish limits at which the harm may out-
weigh the potential beneﬁts, and further research iswarranted to inves-
tigate what these limits may be for nitrate and nitrite. The extensive
monograph by L'Hirondel and L'Hirondel (2002) and several recent ar-
ticles (Lundberg et al., 2004; Bryan et al., 2012; Kapil et al., 2014) pro-
vide a more detailed information for further reading about the
potential harmful effects of nitrate and nitrite.10. Summary and conclusions
Nitrite appears to have considerable potential as a therapeutic agent
to increase the bioavailability of NO under certain conditions such as in
hypoxia, where endogenous NO production via the L-arginine–NOS–NO
pathway may be compromised. Thus, nitrite could conceivably be ap-
plied in conditions such as heart failure due to its vasodilatory capacity,
apparently without the risk of development of tolerance and headache
as documented with organic nitrate treatment, making nitrite perhaps
amore acceptable alternative. Oral nitrate administrationwould appear
to represent an attractive vehicle for nitrite delivery in vivo. The beneﬁ-
cial vasodilatory effects apparent with nitrate and nitrite consumption
through dietary sources may promote vascular health and ward off
CVD. Nitrite therapy is a rapidly expanding area with great potential
for improved clinical outcome in patients, however caution is advised
in the translation of results obtained in animal experimental models
to the clinical setting. A recent multi-centre, double-blind, placebo con-
trolled clinical trial showed that nitrite was ineffective when adminis-
tered intravenously immediately prior to PPCI in patients presenting
with ﬁrst acute STEMI (Siddiqi et al., 2014). Therefore, we need to be
mindful of differences between animal and human physiology as well
as inter-individual differences in responsiveness to nitrite between sub-
jects.Moreover, the handling of nitrite (and nitrate)may differ between
health and disease, posing additional challenges to effectiveness and ap-
plicability of the administered treatment.Financial support
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